Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Colorectal Phase 1 Trials

Indianapolis, Indiana

Phase 1 colorectal cancer trials in Indianapolis, IN

12 Phase 1 colorectal cancer studies are recruiting participants at sites in Indianapolis as of November 17, 2026, according to ClinicalTrials.gov. Colorectal Phase 1 Trials can help you understand your options and connect with a study team.

Call (888) 415-5976
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Indianapolis at a glance

  • 12 studies are recruiting at a site in Indianapolis.
  • By phase: Phase 1 (5), Phase 1/2 (7).
  • By sponsor: industry (11), university, hospital or other (1).
  • Most recent update to one of these records: November 16, 2026.

Studies recruiting in Indianapolis

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Community Health Network
    Registry record
    NCT06324357 · updated
  2. A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Indiana University (IU) Health - Multi-D Oncology Clinic
    Registry record
    NCT07488676 · updated
  3. A Study of LY4337713 in Participants With FAP-Positive Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Indiana University (IU) School of Medicine
    Registry record
    NCT07213791 · updated
  4. A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Community Health Network
    Registry record
    NCT06663319 · updated
  5. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Artios Pharma Ltd
    Study site
    Community Health Network
    Registry record
    NCT04657068 · updated
  6. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #4
    Registry record
    NCT05176483 · updated
  7. Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
    Study site
    Indiana University Simon Comprehensive Cancer Center
    Registry record
    NCT06625775 · updated
  8. Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Community Health Network
    Registry record
    NCT06128551 · updated
  9. A Study of IDP-001 in Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    InduPro, Inc.
    Study site
    Community Cancer Center North
    Registry record
    NCT07602842 · updated
  10. Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

    • Phase 1/2
    • From 12 months, up to 30 years
    • All sexes
    Sponsor
    Children's Oncology Group
    Study site
    Riley Hospital for Children
    Registry record
    NCT04851119 · updated
  11. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Community Health Network, Inc. /ID# 243011
    Registry record
    NCT05005403 · updated
  12. A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    GV20 Therapeutics
    Study site
    Community Health Network, Inc.
    Registry record
    NCT05669430 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Indianapolis, IN on ClinicalTrials.gov.

Ask about studies near Indianapolis

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Colorectal Phase 1 Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 415-5976

or send a short form

How should we reach you?

Call